PELI1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL8071374	0.63	10/20
SCHEMBL3987824	0.67	6/20
Oxyresveratrol (SCHEMBL501690)	0.62	6/20
Oxyresveratrol (SCHEMBL988358)	0.62	6/20
SCHEMBL6795415	0.51	6/20
SCHEMBL4933289	0.49	6/20
SCHEMBL6639041	0.70	5/20
SCHEMBL6638484	0.68	4/20
SCHEMBL878986	0.50	4/20
SCHEMBL6557065	0.45	4/20
SCHEMBL766060	0.67	3/20
SCHEMBL6096125	0.65	3/20
SCHEMBL6096128	0.65	3/20
SCHEMBL6098058	0.65	3/20
SCHEMBL6098062	0.65	3/20
SCHEMBL766012	0.64	3/20
SCHEMBL766046	0.64	3/20
Hydrochloric Acid (SCHEMBL6096228)	0.64	3/20
Hydrochloric Acid (SCHEMBL6096230)	0.64	3/20
SCHEMBL2467808	0.62	3/20

Clinical trials — most relevant to PELI1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)	PHASE1/PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer	PHASE2	UNKNOWN
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Biomarker in Tissue Samples From Patients With Ewing Sarcoma	nan	COMPLETED
Prospective Genetic Study in Patients With Ovarian Insufficiency	nan	UNKNOWN
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome	nan	ACTIVE_NOT_RECRUITING
Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects	nan	WITHDRAWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Novel Genetic Disorders of the Immune System	nan	RECRUITING
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma	nan	WITHDRAWN
PCD New Gene Discovery	nan	COMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Assessment of Candidate Protein Expression in Breast Cancer Specimens	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Metabolic Profiling of Immune Responses in Immune-mediated Diseases	nan	RECRUITING
iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy	nan	COMPLETED
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies	nan	RECRUITING
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma	nan	RECRUITING
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PELI1 binder may also engage these)

Protein	Name	Similarity
Q8C669	—	1.000	Q8C669 →
Q9HAT8	—	1.000	Q9HAT8 →
Q8BST6	—	1.000	Q8BST6 →
Q8L5Y9	—	0.948	Q8L5Y9 →
P11497	—	0.943	P11497 →
Q5SWU9	—	0.942	Q5SWU9 →
RPTOR	Regulatory-associated protein of mTOR	0.942	landscape →
Q9TTS3	—	0.942	Q9TTS3 →
Q28559	—	0.940	Q28559 →
Q5R5F8	—	0.940	Q5R5F8 →
Q9NVE7	—	0.939	Q9NVE7 →
Q96JJ3	—	0.939	Q96JJ3 →
Q8K4Q0	—	0.939	Q8K4Q0 →
Q4R4U1	—	0.938	Q4R4U1 →
B1H2N3	—	0.938	B1H2N3 →
Q99L90	—	0.938	Q99L90 →
Q68FK8	—	0.938	Q68FK8 →
O54956	—	0.937	O54956 →
Q504Q3	—	0.937	Q504Q3 →
MCRS1	Microspherule protein 1	0.937	landscape →
Q6P6Q9	—	0.936	Q6P6Q9 →
P56282	—	0.936	P56282 →
P11029	—	0.936	P11029 →
Q8VCX5	—	0.936	Q8VCX5 →
Q8BPU7	—	0.936	Q8BPU7 →
O70133	—	0.936	O70133 →
Q0J035	—	0.936	Q0J035 →
O88506	—	0.935	O88506 →
ACACA	Acetyl-CoA carboxylase 1	0.935	landscape →
Q39247	—	0.935	Q39247 →